We Update you with the Clock Running. Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explains Patient Family Education and Rights.
Odanacatib, An Investigational Cathepsin K Inhibitor, Reduced Markers Of Bone Turnover In Women With Breast Cancer And Bone Metastases
Bones / Orthopaedics Merck & Co., Inc, Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme or MSD, announced results of a new study in which its investigational selective cathepsin K inhibitor odanacatib reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast cancer that has spread to the bones (bone metastases). Study results were presented today during an oral session at the VII International Meeting on Cancer Induced Bone Disease.
Custom Search
